Kornimate/medical-research-clean huggingface dataset:
screening for asymptomatic portal vein thrombosis and portal hypertension in patients with philadelphia negative myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasms (MPN); Polycythemia Vera (PV); Essential Thrombocythemia (ET); Myelofibrosis (MF)

Summary: this study involves screening for portal vein thrombosis and portal hypertension in patients with philadelphia negative myeloproliferative neoplasms (mpns). these include polycythemia vera (pv), essential thrombocythemia (et), and myelofibrosis. portal vein thrombosis and portal hypertension are serious complications that are often seen in myeloproliferative patients. these complications are usually diagnosed when patients become symptomatic, and are often already at an advanced stage. they can further progress to cause non-reversible damage to the liver, also called cirrhosis of the liver. as a result of this, patients often accumulate fluid in the abdomen which is ascites; and can develop swelling of veins in the lining of the esophagus known as varices. if untreated, varices have the risk of rupturing resulting in life-threatening bleeding. when diagnosed at an advanced stage, the treatment is usually supportive therapy and there are no treatments available at present which can reverse these conditions. this study is looking at screening for these two conditions using doppler ultrasound and upper gastrointestinal endoscopy.


Eligibility criteria:
inclusion criteria: * one of the three classical philadelphia negative myeloproliferative neoplasms (polycythemia vera (pv), essential thrombocythemia (et) and myelofibrosis (mf)) diagnosed according to who or international working group-myelofibrosis research and treatment (iwg-mrt) criteria * palpable spleen length greater than 5 cm below the costal margin in mf (including primary mf or post-polycythemia vera mf (ppv-mf) post-polycythemia vera et (ppv-et)) or palpable spleen of any size in patients with pv or et. * ability to understand and willing to sign a written consent form. * age 18 years or older at time of consent. exclusion criteria: * known history of portal vein thrombosis * known history of budd-chairi syndrome * known history of oesophageal varices * known history of cirrhosis from any cause * known history of active bleeding
clevidipine in the treatment of patients with severe hypertension (velocity)

Conditions: Hypertension

Summary: the purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure, defined as systolic (sbp) \>180 mmhg and/or diastolic blood pressure (dbp) \>115 mmhg assessed on 2 successive occasions 15 minutes apart at baseline, in patients with or without major organ injury, particularly with respect to controlled dose adjustment to desired effect and prolonged continuous infusion. enrollment of patients into the study was to continue until the target goal of 100 patients with at least 18 hours of continuous clevidipine treatment, including a minimum of 50 patients with acute or chronic end-organ injury, was met.


Eligibility criteria:
inclusion criteria: * age 18 years or older * systolic blood pressure \>180 mmhg and/or diastolic blood pressure \>115 mmhg assessed on two successive occasions, 15 minutes apart at baseline * written informed consent exclusion criteria: * sbp ≤180 mmhg and/or dbp ≤115 mmhg * expectation that the patient will not tolerate intravenous antihypertensive therapy for at least 18 hours * known or suspected aortic dissection * administration of an agent for treating hypertension within 2 hours of clevidipine administration * severe hypertension known to be precipitated by use of, or withdrawal from, alcohol or illicit drugs, or intentional overdose of illicit or prescription drugs * positive pregnancy test * intolerance to calcium channel blockers * allergy to soybean oil or egg lecithin * known liver failure or cirrhosis * participation in clinical research studies of other investigational drugs or devices within 30 days of enrollment
effects of esketamine on postoperative behavioral changes in children undergoing tonsillectomy and/or adenoidectomy

Conditions: Behavior Problem

Summary: the goal of this clinical trial is to learn the effect of intravenous esketamine in postoperative negative behavior changes in children compared to placebo (a look-alike substance that contains no drug). it will also learn about the effect of esketamine in emergence delirium. the main questions are: dose esketamine lower the incidence of postoperative negative behavior changes compared to placebo? dose esketamine lower the incidence of emergence delirium compared to placebo? researchers will compare esketamine to placebo to see if esketamine works to treat postoperative negative behavior change and emergence delirium. participants will: receive intravenous esketamine or placebo (a look-alike substance that contains no drug) during anesthesia induction; fill in the post hospitalization behavior questionnaire for ambulatory surgery postoperative 1, 7, and 30

approximately half of children who undergo general anesthesia experience emergence delirium (ed) and postoperative negative behavioral changes (pnbc). there was a positive correlation between delirium during recovery and the change in negative behaviour after the operation. esketamine has sedative, analgesic and anti-traumatic stress effects. based on literature analysis and preliminary trials, this study suggests that intraoperative use of low-dose esketamine may reduce the incidence of emergence delirium and postoperative negative behavior changes in children. this prospective randomized controlled trial was conducted to compare the effect of intravenous esketamine in the incidence of emergence delirium and postoperative negative behavior changes in children compared to placebo (a look-alike substance that contains no drug) to provide a reference for optimizing clinical anesthesia medication regimens.

Eligibility criteria:
inclusion criteria: * american society of aneshesiologists physical status i or ii; * aged 3-7 years; * scheduled for elective tonsillectomy and (or) adenoidectomy. exclusion criteria: * parents refusing to allow their children to participate; * intake of sedative or analgesic medication within 48 hours before surgery; * developmental delay; * psychosis; * body mass index \> 30 kg/m2; * allergy to study drugs; * major life changes 1 month before the operation, such as the divorce of parents, death of parents, moving to a new home, changing to a new kindergarten, etc.; * any other conditions that precluded study inclusion.

Keywords: esketamine postoperative negative behavioral change pediatrics emergence delirium tonsillectomy adenoidectomy
endostar combined with corticosteroid for treatment of radiation-induced brain necrosis in nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: to evaluate the effectiveness and safety of endostar combined with corticosteroids on radiation-induced brain necrosis in nasopharyngeal carcinoma patients. detailed description:

this was a single-arm, open-label study. we aimed to evaluate the effectiveness and safety of endostar combined with corticosteroids on radiation-induced brain necrosis in nasopharyngeal carcinoma patients. magnetic resonance imaging (mri) was performed pre- and post-treatment to define the radiographic response.the primary outcome was a 2-month response rate as determined by mri and clinical symptoms. all of the patients were followed up with for 6 months.

Eligibility criteria:
inclusion criteria: * cytologically or histologically proven nasopharyngeal carcinoma(who 2003 i-iii) . * presence of at least one measurable target lesion (recist rules) in a non irradiated region; * age ≥18 years; * radiation therapy history for histologically confirmed npc administered≥6 months prior to study entry; * radiographic evidence to support the diagnosis of rn with out tumor recurrence or metastases; * patients had never received antiangiogenic agents for rn treatment prior to the screening; * patients had never received corticosteroids for rn treatment prior to the screening; * no evidence of very high intracranial pressure suggestive of a brain hernia requiring surgery routine laboratory studies including urinalysis, complete blood count, liver function, renal function, and coagulation test within a normal range; * to understand and be willing to sign a written informed consent. exclusion criteria: * other types of nasopharyngeal carcinoma; * recurrent nasopharyngeal carcinoma, resection of encephalopathy, metastasis, hepatitis, other malignant tumors, neurovascular diseases, or other diseases of the nervous system; * inadequately controlled diabetes (fbg \> 10mmol/l) and hypertension(systolic blood pressure \> 140 mmhg, diastolic blood pressure \> 90 mmhg); * other severe concurrent disorders that occurred before enrollment (severe or unstable angor, nyha class 3 or 4 congestive heart failure, myocardial infarction occurred within 6 months before enrollment；aortic dissection aortic aneurysm.) active central nervous system hemorrhage; * pregnant or lactating women, women who have not undergone a pregnancy test (within 14 days prior to initial administration), and pregnant women; * patients with a history of severe mental illness or communication disorders.

Keywords: endostar radiation-induced brain necrosis nasopharyngeal carcinoma
oneshot renal denervation registry

Conditions: Hypertension; Heart Failure; Diabetes Mellitus; Sleep Apnea

Summary: this is a multi-center, prospective registry designed to monitor the outcomes of renal denervation with the oneshot device in a real-world patient population.


Eligibility criteria:
inclusion criteria: * patient is an acceptable candidate for renal denervation based upon the instructions for use. * patient is ≥ 18 years old. * patient provided written informed consent. exclusion criteria: * patients who are pregnant, nursing, or planning to become pregnant. * patients who have only one functioning kidney. * allergy to contrast or known hypersensitivity to device materials * patients with renal arteries \< 4 mm in diameter. * patients whose life expectancy is less than the planned period of study involvement.
an observational study on intermittent self catheterisation discontinuation factors in multiple sclerosis patients

Conditions: Multiple Sclerosis

Summary: urinary disorders (ud) are common in multiple sclerosis (ms) and can necessitate using intermittent self catheterisation (isc). it is well experienced by patients, has little impact on daily life and improves quality of life. however, studies are lacking on long-term adherence to this treatment as well as on discontinuation factors. our main objective is to prospectively assessed factors associated with isc discontinuation 2 years after having introduced this technique.

urinary disorders (ud) are common in multiple sclerosis (ms). about 65% of patients suffering from moderate to severe troubles. in case of voiding dysfunction, the reference treatment is based on intermittent self catheterisation (isc). ud in spinal cord injury (sci) patients have been widely studied. they are very common, and are life-threatening in the absence of appropriate care. management of neurological ud (as those occurring in ms) are well defined. isc is the gold standard of bladder emptying method in this pathological context, and has been the subject of numerous studies. in sci, the isc discontinuation rate varies from 52 to 80% according to the published studies, the main factors of continuation being the autonomy to perform the technique, and the continence rate. however, the results are variable. in case of ms, the studies are lacking, the results concerning the discontinuation rate and factors associated with discontinuation are poor. our main objective within the french speaking neurology study group (genulf), is to prospectively assessed factors associated with isc discontinuation 2 years after having introduced this technique. this predictive study will be multicenter, observational, analytical, and prospective and will not modify current clinical practice. we will record clinical and urinary data at each visit (inclusion, 6 weeks, 6 months, 12 months, and 24 months). we will note also if the patient practice isc as prescribed in order to identify discontinuation of the isc.

Eligibility criteria:
inclusion criteria: * patient aged 18 to 65 years * patient with ms * first isc prescription * patient giving informed consent * patient affiliated to the social security system exclusion criteria: * patient who has already tried / practiced isc * patient under safeguard of justice / guardianship / tutorship * pregnant or lactating woman

Keywords: multiple sclerosis urinary disorders intermittent self catheterisation
study of the effect of vx-770 on hyperpolarized helium-3 magnetic resonance imaging in subjects with cystic fibrosis and the g551d mutation

Conditions: Cystic Fibrosis

Summary: cystic fibrosis (cf) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene. the encoded protein, cftr, is an epithelial chloride ion channel responsible for aiding in the regulation of salt and water absorption and secretion in various tissues. although the disease affects multiple organs, the leading cause of mortality is the progressive loss of lung function. obstruction of airways with thick mucus, chronic bacterial infection of the airways, and inflammatory response are all thought to play a role in causing lung damage. through its function as a chloride channel, cftr is believed to be integral in epithelial ion and water transport and hence, maintaining the normal hydration of lung secretions. vx-770 (ivacaftor) is a potent and selective potentiator of wild-type, g551d, f508del, and r117h forms of human cftr. based on in vitro studies and pharmacologic, pharmacokinetic (pk), and safety profiles, vx-770 has been selected for clinical development as a possible treatment for patients with cf. hyperpolarized noble gas magnetic resonance imaging (hg-mri) is a promising new means of assessing lung function by direct imaging of certain non-radioactive isotopes of an inert noble gas, such as helium or xenon. through this technique, high-resolution 3-dimensional images of lung ventilation can be obtained in both pediatric and adult patients during a single short breath-hold following inhalation of the gas. this is a 2-part study to evaluate the effect of vx-770 on hyperpolarized helium-3 magnetic resonance imaging (3he-mri), and to evaluate the safety and efficacy of vx-770 in subjects aged 12 years and older with cf who have the g551d-cftr mutation. part a is a single-blind, placebo-controlled study that includes 4 weeks of vx-770 treatment and 4 weeks of placebo treatment. part b is an open-label, 48 week study of long-term effect of vx 770 on hyperpolarized 3he-mri.


Eligibility criteria:
inclusion criteria: * male or female with cystic fibrosis * must have the g551d-cftr mutation on at least 1 allele * fev1 ≥40% of predicted normal for age, gender, and height at screening * 12 years of age or older * must be able to swallow tablets exclusion criteria: * history of solid organ or hematological transplantation * ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within the 30 days prior to screening * use of inhaled hypertonic saline treatment within 14 days prior to the screening visit * extensive body tattoos or other physical features that will confound mri
comparison between two rates of activation of miniscrew-supported upper jaw expander in adolescents

Conditions: Palatal Expansion Technique; Malocclusion; Posterior Crossbite; Maxillary Hypoplasia

Summary: miniscrew-supported maxillary expanders provide advantages over conventional tooth-supported expanders. however, there is no consensus in the literature regarding their activation protocol. the purpose of the clinical trial is to evaluate and compare the effects of slow and rapid activation rates of miniscrew-supported expanders on the skeletal changes, dento-alveolar changes and the pain experience.

transverse maxillary deficiency is one of the problems that are commonly encountered in the orthodontic practice. miniscrew-supported maxillary expansion represents a promising modality for the treatment of transverse maxillary deficiency. however, controversies still exist regarding the activation protocol. one of these controversies is whether using a slow activation protocol would be more beneficial to the patients compared to a rapid activation protocol. another question that consequently ensues is whether such activation protocol would result in less pain compared to the rapid activation protocol. the null hypothesis of the current study is that there is no difference between slow and rapid activation protocols of miniscrew-supported expander.

Eligibility criteria:
inclusion criteria: * permanent dentition. * participants indicated for skeletal maxillary expansion due to unilateral or bilateral posterior cross bite or maxillary transverse deficiency * good oral hygiene exclusion criteria: * history of previous orthodontic or orthopedic treatment * history of maxillary trauma * patients with congenital craniofacial malformations * patients receiving pharmacological agents or having systemic diseases that might affect the bone metabolism or the pain response

Keywords: rapid palatal expansion slow palatal expansion miniscrew bone-borne expander
effects of high-intensity interval training in patients in hemodialysis

Conditions: Chronic Renal Disease

Summary: the purpose of this study is to evaluate the effects of high intensity interval training compared to moderate exercise training and a control group on exercise capacity and quality of life in patients with end stage renal disease on hemodialysis.


Eligibility criteria:
inclusion criteria: * patients on hemodialysis ≥ 3 months exclusion criteria: * acute infection * systolic bp\>180 mmhg or diabolic bp\>105 mmhg * unstable angina pectoris * serious rhythm disturbances * hyperkalemic (\> 6 mmol/l), * unstable diabetes mellitus * wheelchair * dialyses access on lower extremities * haemoglobin \< 9 g/dl

Keywords: exercise hemodialysis physical therapy high-intensity
effects of graston technique in patients with non specific low back pain

Conditions: Back Pain

Summary: non-specific low back pain upsets individuals of all age gathering and is a most significant provider to illness load everywhere on the world. overseeing rules prescribe emergency to locate the uncommon instances of low back pain that are brought about by actually genuine pathology, thus need demonstrative work-up or proficient arrangement, or both. since non-specific low back pain doesn't have a known pathoanatomical cause and treatment accentuations on diminishing in agony and its meanings. to determine the impacts of graston technique in patients with non-specific low back pain. this examination was quasi experimental study and on the basis of inclusion standards, 20 patients were involved. pnrs and odi used to collect the data. graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of apta. the data was analyzed using spss 21.


Eligibility criteria:
inclusion criteria: * • both genders * age (20-40 years) * patients with non-specific backache * trigger points and tender points at low back region exclusion criteria: * • patients with chronic diseases * degenerative changes in spine * open wounds around the area to be treated * high blood pressure * diabetic neuropathy * cancer (depending on the type and location) * taking anti-coagulants * pregnancy

Keywords: low back pain,pain numeric rating scale,owestry disability index
the long-term study to evaluate the safety of eplerenone in the treatment of hypertension in children aged 6 to 16 years

Conditions: Hypertension

Summary: to assess the long-term safety and toleration of eplerenone in the children aged 6 to 16 years with high blood pressure. the study will last at least 1 year and about 140 patients will participate.


Eligibility criteria:
inclusion criteria: * males and females aged 6 to 16 years * the seated systolic blood pressure greater than or equal to the 95th percentile for age, gender and height, measured on at least 3 separate occasions exclusion criteria: * k/doqi classification of stages of chronic kidney disease equal to 4 or 5 * serum or whole blood potassium \> 5.5. meq/l
study of comprehensive diagnosis and treatment for children precocious puberty

Conditions: Central Precocious Puberty

Summary: this is a prospective, multicentric, comparative, non-randomized interventional study in which subjects diagnosed with central precocious puberty (cpp) and early puberty (ep) were treated for 6 months to compare the effect with gnrha and traditional chinese medicines.

740 girls with cpp and ep participated in this study, all participates were divided into gnrha group, traditional chinese medicines group and blank group. after at least six months therapy with gnrha or traditional chinese medicines, the investigators compare clinical parameters, sex hormone, bone age and ovarian ultrasound in three groups.

Eligibility criteria:
inclusion criteria: 1. premature appearance of secondary sexual characteristics: girls present with development of secondary sexual characteristics before 8, with breast induration as the earliest manifestation. 2. accelerated linear growth: the annual growth rate is higher than normal. 3. advanced bone age: the bone age is 1 or years more than the actual age 4. enlargement of sexual glands: b-mode ultrasonography of pelvic cavity indicates the volumes of the uterus and ovaries have increased, and multiple ovarian follicles with a diameter\>4mm can be found in ovaries; 5. hpga functions have been primed; serum gonadotropin and sexual hormone levels reach pubertal values. 6. subjects should be willing and able to follow the study protocol during the study period. 7. subjects should submit their parents' or guardians' written informed consent before initiation of the study procedure with non-normal medical care. they should understand that subjects or their parents/guardians may withdraw the consent at any time without impairing future medical care. if the child is old enough to read and write, she should submit a separate consent form. exclusion criteria: 1. patients with central nervous system diseases and thyroid diseases; 2. patients with cha-induced precocious puberty; 3. patients with poor compliance.

Keywords: epidemiology treatment molecular pathological mechanism environmental disrupting chemicals
goals of care discussions for hospitalized patients with advanced cancer

Conditions: Metastatic Cancer

Summary: the goal of this study is to better understand gender differences in end-of-life communication between physicians and patients with advanced cancer in the hospital.


Eligibility criteria:
inclusion criteria: * english speaking, have metastatic cancer that has progressed despite treatment exclusion criteria: * cognitive impairment